To evaluate the effect of diltiazem on antipyrine disposition and metabolism, 10 healthy subjects received 1.2 gm antipyrine on two occasions, once while taking no other medications and once during long-term oral diltiazem, 120 mg three times daily. Antipyrine oral clearance was markedly reduced from (mean ± SEM) 41.7 ± 4.1 to 29.9 ± 2.8 ml/min (P < 0.01) during diltiazem treatment, resulting in prolongation of antipyrine elimination t 1 2 from 12.2 ± 1.0 to 16.7 ± 1.3 hours (P < 0.01), with no change in apparent volume of distribution (42.1 ± 4.0 vs. 41.3 ± 3.1 L; not significant). Measurement of urinary antipyrine and metabolites excreted in the urine during 24 hours after the antipyrine dose (percent of total 24-hour excretion) showed increased antipyrine (4.4% ± 1.0% vs. 7.8% ± 1.6%; P < 0.01) during diltiazem treatment with no significant change in proportion of 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrme excretion between trials. Chronic oral diltizem in therapeutic doses markedly impairs antipyrine oxidation. Diltiazem may therefore impair the clearance of other coadministered drugs that undergo hepatic oxidation.
ASJC Scopus subject areas
- Pharmacology (medical)